lenalidomide has been researched along with Hemorrhagic Thrombocythemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonioli, E; Guglielmelli, P; Loscocco, GG; Mannelli, F; Romano, I; Rotunno, G; Vannucchi, AM; Vergoni, F | 1 |
| Abe, T; Fujii, S; Fujita, M; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Nagashima, K; Sakurai, T; Sato, M; Yamada, M; Yoshida, M | 1 |
2 other study(ies) available for lenalidomide and Hemorrhagic Thrombocythemia
| Article | Year |
|---|---|
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Calreticulin; Dexamethasone; Humans; Hydroxyurea; Lenalidomide; Male; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Osteolysis; Primary Myelofibrosis; Remission Induction; Risk Factors; Sequence Deletion; Stomatitis, Aphthous; Thrombocythemia, Essential | 2021 |
Successful treatment of an essential thrombocythemia patient complicated by Sweet's syndrome with combination of chemotherapy and lenalidomide.
Topics: Aged; Blood Cell Count; Bone Marrow; Drug Therapy, Combination; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Nitrosourea Compounds; Skin; Sweet Syndrome; Thalidomide; Thrombocythemia, Essential; Treatment Outcome | 2014 |